Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc. Common Stock (AARD) Revenue
Annual & quarterly revenue history · segment & region breakdown
AARD · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAardvark Therapeutics, Inc. Common Stock trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2022 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Aardvark Therapeutics, Inc. Common Stock receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Aardvark Therapeutics, Inc. Common Stock reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Aardvark Therapeutics, Inc. Common Stock's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AARD revenue · 4 questionsAARD's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Aardvark Therapeutics, Inc. Common Stock SEC filings · GAAP · Aardvark Therapeutics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026